Table 1.
Antibodies used in this study.
| Antibody | Dilution factor | Company |
|---|---|---|
| Akt | 1:2000 | Cell Signaling Technology |
| phospho-Akt | 1:1000 | Cell Signaling Technology |
| p70S6K | 1:1000 | Cell Signaling Technology |
| phospho-p70S6K | 1:1000 | Cell Signaling Technology |
| MHC | 1:1000 | Developmental Studies Hybridoma Bank |
| mTOR | 1:1000 | Cell Signaling Technology |
| phospho-mTOR | 1:1000 | Cell Signaling Technology |
| MyoD | 1:500 | Santa Cruz Biotechnology |
| Myogenin | 1:1000 | Santa Cruz Biotechnology |
| E2A | 1:2000 | Santa Cruz Biotechnology |
| 4E-BP1 | 1:1000 | Cell Signaling Technology |
| phospho-4E-BP1 | 1:1000 | Cell Signaling Technology |
| pan-Cadherin | 1:5000 | Sigma-Aldrich |
| α-Tubulin | 1:2000 | Santa Cruz Biotechnology |
MHC, myosin heavy chain; mTOR, mammalian target of rapamycin.
Cell Signaling Technology (Beverly, MA, USA); Developmental Studies Hybridoma Bank (Iowa, IA, USA); Santa Cruz Biotechnology (Santa Cruz, CA, USA); Sigma-Aldrich(St. Louis, MO, USA).